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Abstract
Adaptive,  cell-mediated  immunity  involves the  presentation  of  antigenic  peptides  on 
class I MHC molecules at the cell surface. This requires an ABC transporter associated 
with antigen processing (TAP) to transport antigenic peptides generated in the cytosol 
into  the  endoplasmic  reticulum (ER) for  loading  onto  class  I  MHC.    Recent  crystal 
structures of bacterial ABC transporters suggest how the transmembrane domains of TAP 
form  a  peptide-binding  cavity that  acquires  peptides  from  the  cytosol,  and following 
ATP-induced conformational changes, the peptide-binding cavity closes to the cytosol 
and instead opens to the ER lumen for peptide release.  Extensive biochemical studies 
show how transport is driven by ATP binding and hydrolysis on an asymmetric pair of 
cytosolic  nucleotide-binding  domains,  which  are  physically  coupled  to  the  peptide-
binding site to propagate conformational changes through the protein.
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Introduction
A  central  component  of  immune  surveillance  is  the  recognition  of  foreign  antigenic 
peptides presented by class I MHC molecules on the surface of infected or otherwise 
aberrant cells (see [1] for a recent review).  Most of these peptides are derived from 
intracellular  proteins  turned  over  and  degraded  in  the  cytosol.    These  peptides  are 
recognized by T lymphocytes when bound to class I MHC molecules at the cell surface, 
and  hence  the  cytosolic  peptides  must  cross  a  membrane  to  gain  access  to  the 
extracellular environment.  This compartmentalization problem is solved during class I 
MHC processing and assembly in the endoplasmic reticulum (ER) by an ATP-driven 
engine dedicated to peptide transport.  The transporter associated with antigen processing 
(TAP), a heterodimer of homologous TAP1 and TAP2 subunits, uses the energy of ATP 
binding and hydrolysis to transport diverse peptides from the cytosol into the ER lumen
[2,3].  In the ER membrane, TAP, chaperones and class I MHC molecules form a large 
peptide loading complex (PLC) that co-localizes peptide transport and loading onto MHC 
molecules [4].    Previous  reviews  have  summarized  much  of  the  biochemical  and 
functional data on TAP (e.g. [5,6]).  In this review, after briefly describing the peptide 
loading complex, we will focus on the structure and mechanism of its keystone, the TAP 
transporter.
The peptide-loading complex
When  intracellular  proteins  are  turned  over  by  ubiquitin-proteasome  mediated 
degradation, short peptides are generated, some of which are transported by TAP into the 
ER lumen for loading on to class I MHC molecules (Figure 1A; see [7] for a recent Page 3 of 22
review).    Prior  to  peptide  loading,  class  I  heavy  chain  and  β2-microglobulin  are 
assembled via interactions with protein disulfide isomerases (PDI), and the lectin-type 
chaperones calnexin and calreticulin [7].  Calreticulin-bound class I MHC heterodimers 
are then recruited into a large peptide-loading complex (PLC) that contains TAP at its 
core [4,8].    Additional chaperones join  the  PLC,  including  ERp57/ER60 (officially 
classified as PDIA3; protein disulfide isomerase family A, member 3) and the class I-
specific chaperone tapasin.  PLC architecture remains controversial [7-9], and further 
analysis is required to clarify the stoichiometry of components and possible dynamic 
changes as peptides are transported and bound to MHC.  Tapasin interacts with the key 
components of the PLC: its C-terminal transmembrane and cytosolic region interacts with 
the TAP subunits [10,11], and its ER lumenal domains interact with class I MHC [11].  
Tapasin facilitates class I MHC loading [12], at least in part by forming a disulfide-linked 
complex with ERp57, an oxidoreductase that assists appropriate disulfide bond formation
[13].  This disulfide bond between the two chaperones sequesters ERp57 activity and 
prevents the enzyme from reducing a critical disulfide bond in the class I MHC peptide-
binding groove [14].  After class I MHC has bound an antigenic peptide, ER-resident 
chaperones are released, allowing the peptide-bound MHC to migrate through the Golgi 
apparatus and onwards to the cell surface.
At the heart of the peptide-loading complex is the TAP transporter.  TAP is a member of 
the large and ubiquitous family of ATP-binding cassette (ABC) transporters, which pump 
diverse  substrates  across  various  cellular  membranes.    All  ABC  transporters  share  a 
common  modular  architecture  of  two  transmembrane  domains  (TMDs)  and  two Page 4 of 22
nucleotide-binding domains (NBDs) arranged from one or more polypeptide chains.  The 
simplest transporters are assembled from identical subunits and hence are symmetric with 
two identical TMDs and NBDs, whereas the more complex eukaryotic transporters tend 
to have non-identical domains, often fused at the genetic level in a single polypeptide.  
TAP  is  a  heterodimer  of  homologous  but  non-equivalent  TAP1  and  TAP2  subunits, 
which each provide a single TMD and NBD [15-17].  The two TMDs and two NBDs of 
ABC  transporters  form  a  core  unit  capable  of substrate  transport,  but  are  often 
supplemented by accessory domains that provide additional functions, such as regulation, 
substrate capture, or binding of associated proteins [18].  Both TAP1 and TAP2 have an 
additional transmembrane, N-terminal accessory domain that binds tapasin during PLC 
assembly [19-21], although these domains are not required for the fundamental task of 
peptide transport [19,21].
A shared general mechanism for ABC transporters
All ABC transporters likely share a common mechanism (see [22] for a recent review).  
The two TMDs form a cavity for substrate binding that alternates between facing one side 
of the membrane for substrate acquisition and the other side for substrate release (Figure 
1B).  This alternating access mechanism is driven by ATP binding to the cytosolic NBDs 
and subsequent ATP hydrolysis (Figure 1B).  Each NBD binds an ATP molecule, and the 
two ATP-bound NBDs form a closed, tight association [23].  The ATP molecules are 
clasped at the interface and provide contacts to both NBDs [24].  When the NBDs are 
closed around ATP, the TMDs form an outward-facing cavity (‘outward’ is defined as the 
side of the membrane opposite the cytosolic NBDs) [25-28].  Following ATP hydrolysis, Page 5 of 22
the NBDs open and the substrate-binding cavity of the TMDs faces inwards [27,29,30]
(Figure 1B).  Importers and exporters use the same basic set of conformations, but differ 
on which states bind the substrate with high or low affinity.
There are now multiple crystal structures of bacterial ABC transporters, both importers 
and exporters, and in inward- and outward-facing conformations [25-30].  Two of these
bacterial  transporters  have  significant homology  to  TAP and  can  therefore  provide 
templates for three-dimensional models: a putative drug exporter (Sav1866; [28]) and a 
lipid flippase (MsbA) that has been crystallized in multiple conformations (some likely 
non-physiological) [27].  The Sav1866 and MsbA structures illustrate the arrangement of 
the four core domains: two TMDs and two NBDs (Figure 2A).  Each TMD consists of a 
bundle of six long helices that extend into the cytoplasm.  Unexpectedly, the TMDs show 
domain-swapping: helices 1 and 2 of one polypeptide chain bundle with helices 3-6 of the 
second polypeptide and vice-versa, so that the both polypeptide chain participate in the 
formation of each bundle of transmembrane helices.  The NBDs form the closed, ATP-
dependent dimer previously observed in structures of isolated NBDs (Figure 2B), and
interact with the TMDs by a short coupling helix (Figure 2).  The implications of this 
coupling helix are discussed below.
The TAP peptide binding site
Various strategies have been used to map residues in TAP that contact antigenic peptide, 
including  chemically  active  peptides  that  cleave  or  cross-link  to  TAP [31] and  the 
identification of a polymorphic site that alters TAP’s peptide specificity [32,33].  When Page 6 of 22
these peptide-binding residues are mapped onto the corresponding residues of Sav1866, 
they cluster at the base of an outward-facing cavity (Figure 2A; [28]).  Structural models 
of TAP, based on the Sav1866 and MsbA structures, support the hypothesis that this 
putative peptide-binding cavity alternates between facing the cytosolic and ER lumenal 
sides of the membrane as the NBDs open and close [34].  While such models suggest 
where peptides bind TAP, the exact mechanism by which TAP selects and binds peptide 
substrates is still unknown, although the peptide specificity of TAP is well-established 
([35] and references therein). Class I MHC molecules present peptides of 8-10 residues 
with  specific amino acids  at anchor positions to provide strong contacts  between the 
peptide and MHC molecule, whereas at other positions the peptide sequence is free to 
vary.  TAP must similarly bind peptides in a manner that provides sufficient affinity but 
allows  peptide  sequence  diversity.    Human  TAP  prefers peptides  with  basic  or 
hydrophobic amino acids at the C-terminus, which complements MHC specificity, and 
has  a weaker  preference  for  basic  residues  near  the  N-terminus.    These preferences 
presumably reflect the chemical nature of critical sites on TAP that grasp the peptide 
substrate.  Hence both TAP and MHC display specificity for certain amino acids at a few 
positions in the peptide substrate to provide affinity, but also recognize a huge diversity 
of peptide sequences to allow presentation of many different epitopes to the immune 
system.  However, TAP favors 8-13-residue peptides, slightly longer than the canonical 
8-10 amino acids that fit onto class I MHC.  These longer peptides are trimmed at their 
N-termini by the ER-associated aminopeptidase (ERAP; [36-38]), producing the required 
length  for  class  I  MHC  binding and  increasing  peptide  sequence  diversity  at  the  N-
terminus.Page 7 of 22
Asymmetry in the TAP ATPase sites refines a model for peptide transport 
As described above, ATP-dependent NBD closure and subsequent ATP hydrolysis-driven 
opening of the NBDs energize the conformational changes in the membrane-spanning 
regions of TAP required for transport (Figure 1B).  Upon NBD closure, two composite 
ATPase sites are formed at the interface between the TAP1- and TAP2-NBDs (Figure 
2B).  The ATPase sites include characteristic motifs found in all ABC transporters and 
many other ATPases [24].  Each NBD first binds ATP via interactions with the Walker A 
motif  which  contacts  the  α- and  β-phosphates  and  coordinates  an  ATP-associated 
magnesium ion, the Walker B motif which contains a critical acidic residue that positions 
and polarizes the hydrolytic water molecule, and the switch motif which contacts the 
labile γ-phosphate.  The second NBD can now interact with this ATP-bound site and 
complete the active site by contributing the D-loop which positions and polarizes the 
hydrolytic water via a backbone carbonyl, and the signature motif which contacts the γ-
phosphate and mediates ATP-dependent NBD association.  Only in the composite active 
site  of  the  closed  NBD  dimer  are  the  hydrolytic  water  molecule  and  γ-phosphate 
appropriately  positioned  for  hydrolysis [24,39].    High  resolution  crystal  structures of 
TAP1-NBD, both as an ADP-bound monomer [40] and as an ATP-bound dimer used as a 
surrogate  model  for  the  physiological  TAP1-/TAP2-NBD  dimer [39],  support  this 
mechanism.
Unlike most bacterial ABC transporters, some motifs for ATP binding and hydrolysis 
show departures from consensus in both TAP1 and TAP2, such that in the context of an Page 8 of 22
ATP-bound TAP dimer, one ATPase site has consensus motifs, while the second ATPase 
site has substitutions away from consensus [39].  The two ATPase sites are referred to as 
the consensus and degenerate sites, respectively.  Within the degenerate site, substitutions 
in the switch and Walker B motifs markedly reduce ATPase activity, while substitutions 
in  the  signature  motif  weaken  ATP-dependent  NBD  association [39].    Because  the 
degenerate site is impaired, the consensus site is the principal driver of NBD closure and 
ATP hydrolysis.  This is supported by multiple studies that introduce damaging mutations 
into the TAP ATPase sites; mutations are partially tolerated in the degenerate site, but 
peptide transport activity  is  lost  when the  equivalent mutations  are introduced  in the 
consensus site [41-44].  This property of having only one consensus ATPase site, while 
the second site has acquired substitutions that impair its activities, is common amongst 
eukaryotic  ABC  transporters.    A  similar  phenomenon  is  seen  in  other  families  of 
oligomeric ATPases, where homo-oligomeric bacterial ATPases with consensus motifs 
have evolved into complex hetero-oligomers with full activity retained in only a subset of 
active sites.  The implications of the evolution toward heterogeneous active sites are not 
fully understood.  It may simply be that the impairment of one ATPase site is tolerated in 
heterodimers.   Alternatively, it may facilitate more complex  functions  and regulatory 
mechanisms.
The  TAP1- and  TAP2-NBDs  also  have  unique  nucleotide  specificities.    TAP1-NBD 
binds both ATP and ADP, similar to most ABC transporter NBDs, whereas the TAP2-
NBD has a strong preference for ADP ([42,45] and E. Procko, A. McFedries and R. 
Gaudet, unpublished data).  However, at some stage during the transport cycle, TAP2 Page 9 of 22
binds and  hydrolyzes ATP,  which  is  critical  for  driving  conformational  changes 
associated with transport [46] - TAP2 forms the main contacts to the ATP hydrolyzed in 
the consensus ATPase site [39].  While it has been suggested that TAP2 only displays a 
preference  for  ADP  when  isolated  from  TAP1  and  that  the  physiological  TAP1/2 
heterodimer  has  no  such  nucleotide  preferences [47],  another  possibility  is that  the 
nucleotide specificity of TAP2 is regulated during a transport cycle.  Using chimeras 
between the TAP1 and TAP2 proteins, it was observed that a short stretch of amino acids 
near the C-terminus is responsible for the unique nucleotide specificities [48].  In the 
TAP1-NBD structure [39,40], these amino acids are distant from the ATP-binding site 
and instead form a hinge-like loop that bridges two subdomains (Figure 2B).  The NBD 
fold  comprises  two  lobes,  an  ATPase subdomain  and  a  helical  subdomain,  that  are
capable of rigid body rotations.  While a crystal structure of TAP2-NBD has yet to be 
determined, the length and residues of the hinge element differ in TAP1 and TAP2.  We 
hence hypothesize that the distinct nucleotide specificities of TAP1 and TAP2 are due to 
different relative orientations of the NBD subdomains, encoded by their unique hinge 
regions.  In crystal structures of full-length bacterial ABC transporters, a short helical 
element from each TMD, called a coupling helix, contacts each respective NBD [22].  
This coupling helix fits in a groove between the two NBD subdomains such that TMD 
motions could direct the NBD subdomains into different orientations (Figure 2).  The 
domain swapping observed in the structure of the Sav1866 TMDs described above, if 
conserved in TAP, would entail an interaction of the TAP1 coupling helix with the TAP2
NBD  and  vice-versa,  possibly  explaining  how  TAP1  seems  to  alter the  nucleotide-
binding preference of TAP2 [47].  This influence of the coupling helix on nucleotide-Page 10 of 22
binding specificity could also be dynamic.  For example, antigenic peptide binding to the 
TMDs could cause a conformational change transmitted, via the coupling helix, to the 
TAP2-NBD, altering its subdomain orientations to promote ADP-ATP exchange or NBD 
closure.
We  recently proposed  a  model  for  the  mechanism  of  TAP illustrated  in  Figure  1B
[34,39].  The transport cycle of TAP begins in an inward-facing conformation with the 
NBDs apart.  The binding of peptide substrate to the cytosolic-facing cavity of the TMDs 
causes  a  conformational  change  that  enables NBD  closure,  perhaps  by  facilitating 
exchange of ADP for ATP on TAP2.  ATP-driven NBD closure is coupled to TMD 
motions that flip the peptide-binding cavity to an outward/lumenal-facing conformation.  
This leads to peptide release, as supported by biochemical experiments indicating that 
TAP has lowest affinity for peptides when the NBDs are trapped in a closed state [31].  
ATP  hydrolysis  in  the  consensus  ATPase  site  (possibly  followed  by  a  nonessential 
hydrolysis  of  ATP  in  the  degenerate site)  causes  the  NBDs  to  re-open,  resetting the 
inward-facing conformation for another transport cycle.
Viral inhibitors of TAP
A number of viruses target TAP to subvert class I MHC presentation and evade immune 
surveillance.  mK3 of murine gammaherpesvirus-68 and UL49.5 of bovine herpesvirus 1
(BHV-1) bind and target TAP for proteasomal degradation [49,50].  Other viral inhibitors 
arrest  TAP  in  a  translocation-incompetent  state.  US6  of  human  cytomegalovirus
(HCMV) and UL49.5 of equine herpesvirus (EHV) types 1 and 4 lock TAP in a state that Page 11 of 22
can still bind antigenic peptides, but block the interaction of TAP with ATP [51-56].  
US6, which interacts with TAP on the ER lumenal side, could propagate its inhibition to 
the  cytosolic  nucleotide-binding  sites  of  TAP  via the  coupling  helices’  proposed 
modulation  of NBD  subdomain  orientation.    The  UL49.5  proteins  of  BHV-1  and 
pseudorabies  virus  (PRV)  arrest  TAP  in  a  state  that  can  still  bind  peptides  without 
preventing ATP interactions [49,51].   Finally, the  cytosolic ICP47 proteins of herpes 
simplex  viruses  (HSV)  block  the  TAP  peptide-binding  cavity  by  competing  with 
antigenic peptides [57,58].  Therefore these viral inhibitors – US6, UL49.5 and ICP47 –
likely all trap TAP in an inward-facing, open-NBDs conformation, blocking the initiation 
of a transport cycle (Figure 3).  This is reminiscent of substrate-mediated trans-inhibition 
observed for some bacterial ABC importers, in which the transported substrate binds a 
cytosolic  regulatory  domain  to  lock  the  transporter  in  the  inward-facing,  open-NBD 
conformation  when  cytoplasmic  substrate  levels  are  high [59,60].    The  viral  TAP 
inhibitors may function analogously to the regulatory domains of these importers, and by 
blocking the transporter prior to ATP-driven NBD closure the inhibitors would avoid
working against the  energy provided  by ATP hydrolysis  to  dissociate the  NBDs.   A 
possible exception to this general inhibition mechanism may be presented by the BNLF2a 
protein of Epstein-Barr virus and its close relatives.  BNLF2a interacts with and locks 
TAP in a conformation that is unable to bind free ATP or peptides [61].  The nucleotide-
and peptide-binding sites may simply be occluded, or alternatively BNLF2a may lock 
TAP in an outward-facing, closed-NBD conformation, in which the now lumenal-facing 
peptide-binding  cavity  has  low  substrate  affinity  and  the  closed  ATPase  sites  are 
inaccessible  for  nucleotide  exchange.    Additional viral  inhibitors  of  this  important Page 12 of 22
transporter for  antigen  presentation will likely  be discovered and will  continue  to  be 
useful tools to determine the molecular mechanism of peptide transport by TAP.
Concluding remarks
Recent bacterial ABC transporter structures have advanced our understanding of 
the  TAP transporter,  how  it  functions  in  the  peptide loading complex,  and how it  is 
inhibited  by  viral  proteins.    In  turn,  TAP  has proven  to  be an  excellent  model  for 
asymmetric  ABC  transporters  because  it  is  readily  amenable  to  biochemical 
experimentation and several viral inhibitors of TAP function are available.  We anticipate 
that  this  reciprocal interaction  between  the  antigen  presentation  and  ABC  transporter 
fields will continue to yield insights into ABC transporter function in antigen presentation 
and beyond.  
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Figure legends
Figure 1.  Antigenic peptide transport and loading
A. Nascent  class  I  MHC  heavy  chains  and  β2-microglobulin  are  assembled  with 
assistance from numerous chaperones (a).  The MHC heterodimer is then recruited into 
the  TAP-containing  PLC  via  interactions  with  tapasin  (b).    Peptides  generated  by 
ubiquitin-proteasome mediated  protein  turnover  (c),  some  subsequently  trimmed  by 
cytosolic peptidases [62], are transported by TAP from the cytosol into the ER lumen (d).  
These peptides are bound by class I MHC, some after further trimming in the ER by 
ERAP, causing the fully folded class I MHC-peptide complexes to shed ER-associated 
chaperones (e).  The peptide-MHC molecules migrate to the cell surface (f and g) where 
they are scanned by CD8
+ T cells.  B. A model of peptide transport begins with TAP in 
an inward/cytosol-facing conformation with the NBDs open.  A peptide binds a cytosol-
facing cavity formed by the TMDs, causing a conformational change that is transmitted 
to the NBDs.  This conformational change permits ATP-dependent NBD closure, perhaps 
by facilitating exchange of ADP on TAP2 for ATP.  As the NBDs close, the peptide-
binding cavity closes to the cytosol and opens to the ER lumen, creating the closed, 
outward-facing  conformation  of  TAP.    Peptide affinity  is  markedly  reduced  in  this 
conformation, and the peptide is hence released into the ER.  ATP hydrolysis in the 
consensus ATPase site is sufficient to destabilize the closed NBDs (hydrolysis may also 
occur in the degenerate ATPase site, but this is not essential), which re-open to generate 
the resting conformation.Page 14 of 22
Figure 2. Structural information on TAP
A.  Ribbon  representation  of  the  Sav1866 crystal  structure,  a  TAP  homologue  from 
bacteria, with closed NBDs and an outward-facing cavity.  The cavity (indicated with a 
cone)  has  a  roughly  V-shaped  opening  that  faces  the  top  of  the  structure  in  this 
orientation.  The  approximate  position  of  the  membrane  is  shaded  blue.  Positions 
equivalent  to  those  that  bind  antigenic  peptides  in  TAP  are  indicated  with  colored 
spheres, including a polymorphic site that alters TAP peptide specificity (blue; [32,33]), a 
site that is cleaved by reactive peptides (yellow; [31]), and a site that can cross-link to 
cysteine-containing peptides (red; [31]).  These positions are near the base of the cavity, 
and are predicted to be accessible for peptide binding when the conformation changes to 
expose the cavity to the inside/cytosol.  The coupling helices from the TMDs that interact 
with the NBDs are shown as solid cylinders.  B. Homology model of TAP1-NBD bound 
to  TAP2-NBD  in  the  closed  conformation  with  ATP  at  the  interface  [63].    Each 
composite ATPase site is formed by Walker A (dark blue), Walker B (purple) and switch 
(red) motifs from one NBD, and signature (yellow) and D-loop (cyan) motifs from the 
second NBD, highlighted on the top, degenerate ATPase site.  The NBD fold has ATPase 
and helical subdomains (labeled for TAP2), and a coupling helix (CH, represented with a 
cylinder) from a TMD fits in the groove between the two subdomains, such that the TMD 
conformation could alter the subdomain orientations.  The hinge elements that determine 
the unique nucleotide-binding specificities of TAP1 and TAP2, possibly by setting the 
preferred subdomain orientations, are colored brown.Page 15 of 22
Figure 3.  Viral inhibition of TAP
Several viral proteins inhibit TAP by arresting the transporter in the resting conformation, 
with the NBDs open and the peptide-binding cavity facing  the cytosol.  HSV ICP47 
competitively blocks the peptide-binding site (A), UL49.5 of BHV-1 and PRV arrest the 
transporter (B), and HCMV US6 prevents interactions with ATP while still permitting 
ADP binding (C; the UL49.5 proteins of EHV-1/4 also prevent ATP binding).  These 
viral inhibitors arrest TAP analogously to substrate-mediated trans-inhibition of certain 
bacterial ABC transporters, in which the transported substrate binds cytosolic regulatory 
domains to lock the transporter in the inward-facing, open-NBDs conformation.  Shown 
is the crystal structure of a trans-inhibited tungstate/molybdate transporter (ModBC) [59], 
with tungstate ions bound to the cytosolic regulatory domains (D).Page 16 of 22
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